Inceptionr LLC Makes New Investment in Neurocrine Biosciences, Inc. $NBIX

Inceptionr LLC bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 1,910 shares of the company’s stock, valued at approximately $240,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. XTX Topco Ltd raised its holdings in shares of Neurocrine Biosciences by 27.9% during the 2nd quarter. XTX Topco Ltd now owns 25,017 shares of the company’s stock worth $3,144,000 after buying an additional 5,463 shares in the last quarter. CreativeOne Wealth LLC raised its stake in Neurocrine Biosciences by 24.5% during the second quarter. CreativeOne Wealth LLC now owns 11,935 shares of the company’s stock worth $1,500,000 after acquiring an additional 2,350 shares in the last quarter. Summit Global Investments boosted its stake in shares of Neurocrine Biosciences by 5.9% in the 2nd quarter. Summit Global Investments now owns 11,516 shares of the company’s stock valued at $1,447,000 after purchasing an additional 638 shares in the last quarter. Prudential Financial Inc. grew its holdings in shares of Neurocrine Biosciences by 21.8% during the 2nd quarter. Prudential Financial Inc. now owns 145,330 shares of the company’s stock valued at $17,798,000 after purchasing an additional 26,030 shares during the last quarter. Finally, Coldstream Capital Management Inc. increased its position in Neurocrine Biosciences by 3.4% during the 2nd quarter. Coldstream Capital Management Inc. now owns 3,775 shares of the company’s stock worth $474,000 after purchasing an additional 125 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Trading Up 0.3%

Shares of NBIX opened at $152.00 on Friday. The company has a market capitalization of $15.16 billion, a PE ratio of 36.36, a PEG ratio of 0.94 and a beta of 0.22. Neurocrine Biosciences, Inc. has a 12 month low of $84.23 and a 12 month high of $157.67. The stock’s 50-day moving average price is $142.87 and its two-hundred day moving average price is $134.93.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.59. The company had revenue of $794.90 million during the quarter, compared to analysts’ expectations of $746.61 million. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.The business’s quarterly revenue was up 27.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.81 earnings per share. Equities research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, CEO Kyle Gano sold 300 shares of the firm’s stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $141.97, for a total transaction of $42,591.00. Following the completion of the transaction, the chief executive officer owned 140,407 shares in the company, valued at approximately $19,933,581.79. This trade represents a 0.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William H. Rastetter sold 18,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $151.82, for a total transaction of $2,732,760.00. Following the completion of the transaction, the director owned 40,360 shares in the company, valued at $6,127,455.20. This trade represents a 30.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 33,300 shares of company stock valued at $4,925,901. 4.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

NBIX has been the topic of a number of research analyst reports. Weiss Ratings restated a “hold (c+)” rating on shares of Neurocrine Biosciences in a research report on Wednesday, October 8th. Zacks Research raised Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 15th. Wall Street Zen upgraded Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 2nd. Needham & Company LLC increased their target price on Neurocrine Biosciences from $170.00 to $184.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Finally, Morgan Stanley cut their price target on Neurocrine Biosciences from $178.00 to $173.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $170.53.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.